Published in Biochem J on August 15, 1986
Cisplatin inhibition of anthrax lethal toxin. Antimicrob Agents Chemother (2006) 0.89
Modification of the tandem reactive centres of human inter-alpha-trypsin inhibitor with butanedione and cis-dichlorodiammineplatinum(II). Biochem J (1988) 0.80
Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. J Clin Invest (1996) 0.75
Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature (1979) 17.18
Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A (1979) 11.19
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
Modification of histidyl residues in proteins by diethylpyrocarbonate. Methods Enzymol (1977) 4.25
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Studies of the reticuloendothelial system (RES). I. Measurement of the phagocytic capacity of the RES in man and dog. J Clin Invest (1963) 2.67
Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. J Biol Chem (1981) 2.15
Characterization of alkylamine-sensitive site in alpha 2-macroglobulin. Proc Natl Acad Sci U S A (1979) 2.05
Model of alpha 2-macroglobulin structure and function. Proc Natl Acad Sci U S A (1985) 1.79
A thiol-ester in alpha 2-macroglobulin cleaved during proteinase complex formation. FEBS Lett (1980) 1.70
Physical properties of human alpha 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta (1982) 1.49
Selective diminution of the binding of mannose by murine macrophages in the late stages of activation. J Biol Chem (1982) 1.45
Demonstration of an alpha2-macroglobulin receptor in human fibroblasts, absent in tumor-derived cell lines. J Biol Chem (1979) 1.45
Primary structure of human alpha 2-macroglobulin. V. The complete structure. J Biol Chem (1984) 1.40
Further characterization of the covalent linking reaction of alpha 2-macroglobulin. Biochem J (1981) 1.35
Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. Science (1982) 1.31
Evidence for similar conformational changes in alpha 2-macroglobulin on reaction with primary amines or proteolytic enzymes. Biochem J (1982) 1.19
Macrophages. Methods Enzymol (1979) 1.10
Binding of alpha 2-macroglobulin to hepatocytes: mechanism of in vivo clearance. Biochem Biophys Res Commun (1985) 1.07
Characterization of functional human alpha 2-macroglobulin half-molecules isolated by limited reduction with dithiothreitol. Biochemistry (1983) 0.96
Chemical and structural modifications of alpha 2-macroglobulin: effects on receptor binding and endocytosis studied in an in vivo model. Ann N Y Acad Sci (1983) 0.94
Changes in the binding of "fast"-form alpha 2-macroglobulin to 3T3-L1 cells after differentiation to adipocytes. Biochemistry (1984) 0.92
Effects of diethyldithiocarbamate and nine other nucleophiles on the intersubunit protein cross-linking and inactivation of purified human alpha 2-macroglobulin by cis-diamminedichloroplatinum(II). Cancer Res (1984) 0.88
Purification and characterization of frog alpha-macroglobulin: receptor recognition of an amphibian glycoprotein. Biochemistry (1985) 0.87
Relation of internal thioesters to conformational change and receptor-recognition site in alpha 2-macroglobulin complexes. Biochem J (1982) 0.87
Cell association and degradation of alpha 2-macroglobulin-trypsin complexes in hepatocytes and adipocytes. Biochim Biophys Acta (1983) 0.86
Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule. J Biol Chem (1983) 0.84
Interactions of platinum complexes with the essential and nonessential sulfhydryl groups of thymidylate synthetate. Biochemistry (1977) 0.83
Inactivation of the plasma protease inhibitor alpha 2-macroglobulin by the antitumor drug cis-dichlorodiamineplatinum(II). J Biol Chem (1981) 0.80
Altered clearance of human alpha 2-macroglobulin complexes following reaction with cis-dichlorodiamineplatinum(II). Biochim Biophys Acta (1981) 0.79
PtCl24-: a methionine-specific label for protein crystallography. J Mol Biol (1969) 0.78
Monoclonal antibodies toward the receptor-recognition site on alpha 2-macroglobulin complexes. Ann N Y Acad Sci (1983) 0.77
Proteolysis at a lysine residue abolishes the receptor-recognition site of alpha 2-macroglobulin complexes. FEBS Lett (1982) 0.76
Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol (1999) 3.60
Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol (2000) 2.59
Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem (1973) 2.45
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol (1999) 2.35
Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. J Biol Chem (1981) 2.15
Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A (1999) 1.95
Pyogenic granuloma-like lesion associated with topical tazarotene therapy. J Am Acad Dermatol (2000) 1.94
Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues. J Biol Chem (1996) 1.94
Absence of human papillomavirus in squamous cell carcinomas of nongenital skin from immunocompromised renal transplant patients. Arch Dermatol (1993) 1.89
Hepatic receptor that specifically binds oligosaccharides containing fucosyl alpha1 leads to 3 N-acetylglucosamine linkages. Proc Natl Acad Sci U S A (1978) 1.87
Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol (1980) 1.85
Waiting times to see a dermatologist are perceived as too long by dermatologists: implications for the dermatology workforce. Arch Dermatol (2001) 1.84
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A (2001) 1.83
Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. N Engl J Med (1980) 1.81
Model of alpha 2-macroglobulin structure and function. Proc Natl Acad Sci U S A (1985) 1.79
Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem (1998) 1.78
A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class II compartments. J Cell Biol (1995) 1.78
Career characteristics of graduates of a Medical Scientist Training Program, 1970-1990. Acad Med (1996) 1.58
Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. J Clin Invest (1979) 1.55
Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol (1998) 1.53
Oxidative dissociation of human alpha 2-macroglobulin tetramers into dysfunctional dimers. J Biol Chem (1994) 1.53
Only 33% of visits for skin disease in the US in 1995 were to dermatologists: is decreasing the number of dermatologists the appropriate response? Dermatol Online J (1998) 1.52
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci (2001) 1.52
Physical properties of human alpha 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta (1982) 1.49
Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem (1977) 1.47
Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol (1992) 1.47
The subunit structure of normal and hemophilic factor VIII. J Clin Invest (1973) 1.46
Selective diminution of the binding of mannose by murine macrophages in the late stages of activation. J Biol Chem (1982) 1.45
A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci (1995) 1.44
The effect of plasmin on the subunit structure of human fibrinogen. J Biol Chem (1972) 1.44
Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem (1985) 1.42
Depression is not common in isotretinoin-treated acne patients. J Dermatolog Treat (2004) 1.42
Targeting of SNAP-23 and SNAP-25 in polarized epithelial cells. J Biol Chem (1998) 1.42
Oral griseofulvin remains the treatment of choice for tinea capitis in children. Pediatr Dermatol (2000) 1.41
Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol (2000) 1.40
Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. Br J Dermatol (2009) 1.40
Use of clotrimazole/betamethasone diproprionate by family physicians. Fam Med (2000) 1.38
Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg (2001) 1.37
HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci U S A (1998) 1.36
Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol (2008) 1.35
alpha 2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest (1994) 1.33
Drafting the Genetic Privacy Act: science, policy, and practical considerations. J Law Med Ethics (1995) 1.31
Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. Science (1982) 1.31
Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol (2003) 1.31
The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem (1971) 1.30
Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol (2001) 1.29
Analysis of inter-alpha-trypsin inhibitor and a novel trypsin inhibitor, pre-alpha-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem (1989) 1.29
Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry (1989) 1.28
Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface. J Biol Chem (1994) 1.28
Syntaxin 11 is associated with SNAP-23 on late endosomes and the trans-Golgi network. J Cell Sci (1999) 1.24
The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest (1971) 1.22
Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol (1988) 1.20
Regulation of macrophage alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma. J Clin Invest (1993) 1.20
Effects of bacterial lipopolysaccharide on the hydrolysis of phosphatidylinositol-4,5-bisphosphate in murine peritoneal macrophages. J Immunol (1987) 1.19
Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer (1996) 1.19
SNAP-23 and SNAP-25 are palmitoylated in vivo. Biochem Biophys Res Commun (1999) 1.19
A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal Biochem (1983) 1.19
Diagnosed skin diseases among migrant farmworkers in North Carolina: prevalence and risk factors. J Agric Saf Health (2007) 1.19
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. J Neuropathol Exp Neurol (1982) 1.18
Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem (1997) 1.17
SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion. J Biol Chem (1997) 1.17
Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem (1991) 1.16
An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest (1991) 1.15
Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem (1996) 1.14
Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest (1991) 1.14
Targeting of SNAP-25 to membranes is mediated by its association with the target SNARE syntaxin. J Biol Chem (2000) 1.12
Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem (1991) 1.12
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol (2000) 1.12
Characterization of diaper dermatitis in the United States. Arch Pediatr Adolesc Med (2000) 1.12
Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol (2001) 1.12
Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem (1994) 1.11
Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. J Histochem Cytochem (1982) 1.10
Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene (2006) 1.10
Intracellular redirection of plasma membrane trafficking after loss of epithelial cell polarity. Mol Biol Cell (2000) 1.10
Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3. Thromb Res (1985) 1.09
Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors. Biochem J (1983) 1.08
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J (1996) 1.08
The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. J Biol Chem (2000) 1.08
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer (1994) 1.08
Anger and acne: implications for quality of life, patient satisfaction and clinical care. Br J Dermatol (2004) 1.07
Binding of alpha 2-macroglobulin to hepatocytes: mechanism of in vivo clearance. Biochem Biophys Res Commun (1985) 1.07
Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol (2002) 1.06
Purification and properties of hog liver 4-hydroxyphenylpyruvate dioxygenase. Arch Biochem Biophys (1982) 1.05
The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J Biol Chem (1999) 1.05
Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem (1993) 1.05
Catabolism of human tissue plasminogen activator in mice. Blood (1985) 1.05